kras inhibitor-10

KRAS inhibitor-10 (WO2021005165 A1, compound 11) is a potent and selective inhibitor of RAS proteins, with a specific focus on KRAS proteins. This orally active anti-cancer agent demonstrates strong efficacy in cancer research, specifically in pancreatic cancer, breast cancer, multiple myeloma, leukemia, and lung cancer. KRAS inhibitor-10 is classified as a tetrahydroisoquinoline compound. Its inhibitory properties provide valuable insights and potential therapeutic applications in the field of oncology [1].

KRAS G12D Inhibitor 10 is a potent agent targeting the KRAS G12D mutation, a variant in the Ras protein family crucial for cellular growth and development. This compound shows promise for investigating cancers mediated by KRAS G12D.

MINA53 inhibitor (Compound 10) is an inhibitor of MINA53.

KRAS G12C inhibitor 16 is a potent KRAS G12C inhibitor with potential anticancer and antitumor activity, inhibits cancer cell proliferation, and can be used in the study of lung cancer.

KRas G12C inhibitor 1 is a compound that inhibits KRas G12C.

KRAS G12D inhibitor 7, is a highly potent inhibitor specifically targeting KRAS G12D.

Tuberculosis Inhibitor 10 moderately inhibits the enzyme MSMEG_6649 and potentiates the antimycobacterial activity of PAS [1].

KRAS mutant protein inhibitor 1 is a KRAS mutant protein inhibitor for potential treatment in cancer.

BRD4 Inhibitor-10 is an inhibitor of BRD4-BD1 (IC50: 8 nM).

KRAS G12D Inhibitor 17 (example 8), a quinazoline-linked (4R)-4-hydroxy-L-prolinamide compound, acts as a proteolysis targeting chimera (PROTAC) [1], specifically inducing degradation of the G12D-mutation KRAS protein.

KRAS G12C inhibitor 56, a powerful inhibitor of SOS1 with an inhibitory concentration (IC50) of 1.6 nM, holds promise for use in cancer research.

KRAS G12D inhibitor 5 is a KRAS G12D inhibitor for the potential treatment of pancreatic cancer.

KRAS G12C inhibitor 19 is a potent KRAS G12C inhibitor that shows anti-tumor activity in cellular assays, and the family inhibits tumor growth.

KRAS G12D inhibitor 6 is an efficacious compound that effectively inhibits KRAS G12D.

KRAS G12C mutant protein inhibitor A-1 can be used in studies about Ras.

KRAS G12C inhibitor 1R can be used in studies about Ras.

KRAS G12C inhibitor 18 is a potent, orally active compound that inhibits KRAS G12C and exhibits anti-tumor activities.

Compound 13, a topoisomerase I inhibitor 10, selectively inhibits leishmanial topoisomerase IB and exhibits antileishmanial activity. Specifically, it demonstrates efficacy against L. donovani promastigotes with an IC50 value of 27.91 μM [1].

KRAS inhibitor FB9 can be used in studies about Ras.

KRAS inhibitor-18 (compound 3-10) is a potent inhibitor of KRAS G12C (IC50: 4.74 μM). KRAS inhibitor-18 exhibited p-ERK inhibition in MIA PaCA-2, A549 cells with IC50s of 66.4, 11.1 μM respectively. KRAS inhibitor-18 has potential for pancreatic, colorectal and lung cancer studies.

KRAS inhibitor-14 is a potent inhibitor of KRAS G12C (IC50: 0.249 μM). KRAS inhibitor-14 exhibited p-ERK inhibition in MIA PaCA-2, A549 cells with IC50s of 1.12, >33.3 μM, respectively. KRAS inhibitor-14 has potential to be investigated in pancreatic, colorectal and lung cancers.

KRAS G12C Inhibitor 37, a potent inhibitor of KRAS G12C, targets the Ras family of proteins, crucial for intracellular signaling related to growth and development. This compound holds potential for research into cancers mediated by KRAS G12C.

KRAS G12C inhibitor 20 is a KRAS G12C inhibitor.

KRAS inhibitor-3, an efficacious inhibitor of both wild-type (WT) and oncogenic KRAS mutations, exhibits high-affinity binding (K D: 0.28 μM for KRAS WT, 0.63 μM for KRAS G12C, 0.37 μM for KRAS G12D, and 0.74 μM for KRAS Q61H). Additionally, it impedes the interaction between KRAS and Raf, highlighting its potential as a targeted therapeutic agent in KRAS-mutant cancers.

KRAS inhibitor-11 is a KRAS inhibitor .

FSH receptor-binding inhibitor fragment (bi-10) is a potent antagonist that inhibits the binding of follicle-stimulating hormone (FSH) to its receptor (FSHR), modifying FSH activity at the receptor level. It suppresses ovulation and induces follicular atresia in mice. Furthermore, this compound holds potential for curbing ovarian cancer carcinogenesis by reducing the overexpression of FSHR and estrogen receptor beta (ERβ) in the ovaries [1].

KRAS G12C inhibitor 34 is an inhibitor of KRAS G12C that can be used to study cancer research.

KRas G12C inhibitor 3 is a compound that inhibits KRas G12C.

KRAS G12C inhibitor 43 is a potent inhibitor of KRAS G12C and inhibits the migration and proliferation of H358 cells (IC50: 0.001-1 μM μM), A549 cells (IC50>1 μM) and HCC cells (IC50>1 μM).

KRas G12C inhibitor 4 is a compound that inhibits KRas G12C.

KRAS G12C inhibitor 22 is a KRAS G12C inhibitor.

KRAS G12C inhibitor 49 is an orally active KRAS G12C inhibitor that exhibits antitumour effects.

KRAS G12D inhibitor 9 is a potent inhibitor of KRAS G12D. Among them, the RAS protein family is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 9 shows research potential for KRAS G12D-mediated cancer.

Bromodomain inhibitor-10 (compound 128) is a highly potent inhibitor of bromodomain activity. It exhibits strong binding affinity with K d values of 15.0 nM and 2500 nM for BRD4-1 and BRD4-2, respectively. Furthermore, Bromodomain inhibitor-10 effectively inhibits the production of IL12p40 [1].

KRAS inhibitor-12 (compound 6-1) is a potent inhibitor of KRAS G12C (IC50: 0.537 μM). KRAS inhibitor-12 exhibits p-ERK inhibition in MIA PaCA-2, A549 cells with IC50 values of 1.3, 3.7 μM respectively. KRAS inhibitor-12 has potential to be studied in pancreatic, colorectal and lung cancers.

KRAS inhibitor-8 is a potent KRAS G12C inhibitor.

KRAS inhibitor-17 (compound 3-9) is a potent inhibitor of KRAS G12C (IC50: 3.37 μM). KRAS inhibitor-17 exhibits p-ERK inhibition with IC50 = 9.25 μM in MIA PaCA-2 cells and >33.3 μM in A549 cells. KRAS inhibitor-17 has the potential to be studied in pancreatic, colorectal and lung cancers.

KRAS G12C inhibitor 17 is a potent KRAS G12C inhibitor.

KRAS G12C inhibitor 50 is a KRAS G12C inhibitor (IC50: 46.7 nM).

HIV-1 Integrase Inhibitor 10, an orally active allosteric integrase inhibitor (ALLINI), effectively inhibits the NLRepRluc virus's viral outgrowth in MT-2 cells, exhibiting EC50 values of 3-5 nM. This compound is utilized in the research of Human Immunodeficiency Virus-1 (HIV-1).

KRAS G12C Inhibitor 39, a potent antagonist, specifically targets the KRAS G12C mutation, a prime focus in pharmaceutical cancer research. This compound shows promise for investigating KRAS G12C-mediated cancer.

KRAS G12C Inhibitor 35 is a potent suppressor of KRAS G12C, targeting a crucial member of the Ras protein family which significantly impacts cellular growth and development. This compound holds promise for investigating cancer driven by KRAS G12C mutations.

KRAS G12C Inhibitor 41 is a potent agent targeting the KRAS G12C mutation within the Ras family of proteins, which are crucial for intracellular signaling related to growth and development. This compound holds significant potential for advancing research in cancers mediated by KRAS G12C.

KRAS G12C Inhibitor 48 is a potent inhibitor targeting the KRAS G12C mutation, exhibiting an IC50 value of 639.91 nM. Demonstrating antiproliferative activity, KRAS G12C Inhibitor 48 (0-50 µM) yields IC50 values of 0.796 µM, 6.33 µM, and 16.14 µM against H358, H23, and A549 cell lines, respectively.

KRAS G12D Inhibitor 3 TFA, exhibiting an inhibitory concentration (IC50) of less than 500 nM, is effective as an antitumor agent.

KRas G12R Inhibitor 1 (compound 3) is a selective covalent inhibitor targeting the KRas G12R mutation, leveraging the high nucleophilicity of mutant cysteines to bind irreversibly within the K-Ras Switch II region. This compound is utilized in cancer research [1].

KRAS G12C inhibitor 44 is a potent, orally active KRAS G12C inhibitor. KRAS G12C inhibitor 44 exhibits anti-proliferative effects in MIA PaCA-2 (IC50: 0.016 μM), H358 cells (IC50: 0.028 μM). inhibitor 44 has anti-tumour activity in vivo.

GSK-3β inhibitor 10 has skin-whitening, anti-oxidizing and PPAR activities.

BTK inhibitor 10 is a potent and orally active BTK inhibitor. It has the potential for rheumatoid arthritis treatment.

KRAS G12C inhibitor 21 is a KRAS G12C inhibitor.